One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis.

ABSTRACT:

Background/aims

To evaluate the efficacy and safety of the PreserFlo MicroShunt glaucoma device in a multicentre cohort study.

Methods

All consecutive patients who received the microshunt with mitomycin-C (MMC) 0.4 mg/mL from May 2019 to September 2020 in three UK tertiary centres. Primary outcome at 1 year was a complete success, with failure defined as intraocular pressure (IOP) >21 mmHg or <20% reduction, IOP≤5 mmHg with any decreased vision on two consecutive visits, reoperation or loss of light perception vision. Secondary outcomes were IOP, best-corrected visual acuity, medications, complications, interventions and reoperations. We also performed subgroup analyses for severe glaucoma and assessed risk factors for failure.

Results

104 eyes had 1-year follow-up. C

SUBMITTER: Tanner A 

PROVIDER: S-EPMC10359526 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature